Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis

Journal of Immunology

Volumn 165, Issue 5, 2000, Pages 2886-2894

  Griffith, T S ^a   Anderson, R D ^a   Davidson, B L ^a   Williams, R D ^a   Ratliff, T L ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSE; CASPASE 8; CASPASE INHIBITOR; LIPOCORTIN 5; RECOMBINANT CYTOKINE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE THERAPY; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL DESTRUCTION;

EID: 0034283942     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.5.2886     Document Type: Article

References (61)

1. Tumor necrosis factor receptor superfamily members and their ligands
2. A family of ligands for the TNF receptor superfamily
3. Apoptosis signaling by death receptors
4. The role of cachectin/TNF in endotoxic shock and cachexia
5. Induction of apoptosis in mature T cells by tumor necrosis factor
6. Fas ligand mediates activation-induced cell death in human T lymphocytes
7. Fas ligand-induced apoptosis as a mechanism of immune privilege
8. Melanoma cell expression of Fas (Apo-1/CD95) ligand: Implications for tumor immune escape
9. Identification and characterization of a new member of the TNF family that induces apoptosis
10. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family
11. The receptor for the cytotoxic ligand TRAIL
12. An antagonist decoy receptor and a death domain-containing receptor for TRAIL
13. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors
14. TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL
15. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL
16. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family
17. The novel receptor TRAIL-R4 induces NFκB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain
18. A novel receptor for Apo2L/TRAIL contains a truncated death domain
19. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signaling
20. Tumoricidal activity of TRAIL in vivo
21. Safety and antitumor activity of recombinant soluble Apo2 ligand
22. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11
23. Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with down-regulation of its proapoptotic activity and loss of liver toxicity
24. Lethal effect of the anti-Fas antibody in mice
25. + T cell-mediated cytotoxicity
26. Altered vascular function after adenovirus-mediated overexpression of endothelial nitric oxide synthase
27. Isolation of adenovirus type 5 host range deletion mutants defective for transformation of rat embryo cells
28. Comparison of in vitro cell cytotoxic assays for tumor necrosis factor
29. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis
30. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: Inhibition by overexpression of Bcl-2 and Abl
31. 5 promote adenovirus internalization but not virus attachment
32. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5
33. HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses
34. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-κB pathway
35. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-κB
36. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells
37. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages
38. Different populations of macrophages use either the vitronectin receptor or the phosphatidylserine receptor to recognize and remove apoptotic cells
39. Binding of annexin V/placental anticoagulant protein I to platelets: Evidence for phosphatidylserine exposure in the procoagulant response of activated platelets
40. Annexins: The problem of assessing the biological role for a gene family of multifunctional calcium and phospholipid-binding proteins
41. Interleukin-7/B7.1-encoding adeno-viruses induce rejection of transplanted by not nontransplanted tumors
42. Eradication of primary murine fibrosarcomas and induction of systemic immunity by adenovirus-mediated interferon β gene therapy
43. Adenovector-medialed gene delivery of interleukin-2 in metastatic breast cancer and melanoma: Results of a phase 1 clinical trial
44. Regional treatment of hepatic micrometastasis by adenovirus vector-mediated delivery of interleukin-2 and interleukin-12 cDNAs to the hepatic parenchyma
45. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: Suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model
46. Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12
47. Prodrug activation gene therapy and external beam irradiation in the treatment of prostate cancer
48. Efficacy of adenovirus-mediated CD/5-FC and HSV-1 thymidine kinase/ganciclovir suicide gene therapies concomitant with p53 gene therapy
49. Gene transfer of Fas ligand induces tumor regression in vivo
50. Treatment of experimental glioma by administration of adenoviral vectors expressing Fas ligand
51. Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells
52. TRAIL: A molecule with multiple receptors and control mechanisms
53. Inhibition of death receptor signals by cellular FLIP
54. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes
55. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
56. 5 and CD36, and cross-present antigens to cytotoxic T lymphocytes
57. A 'stealth effect': Adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions
58. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand
59. Fas ligand expression in primary colon adenocarcinomas: Evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer
60. The Fas counterattack in vivo: Apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma
61. Cancer statistics, 1999